BR100 Decreased By (-4.8%)
BR30 Decreased By (-6.39%)
KSE100 Decreased By (-3.16%)
KSE30 Decreased By (-3.23%)
BECO 5.00 Decreased By ▼ -0.27 (-5.12%)
BML 61.00 Decreased By ▼ -3.54 (-5.48%)
BOP 29.75 Decreased By ▼ -3.29 (-9.96%)
CNERGY 6.57 Decreased By ▼ -0.44 (-6.28%)
DCL 9.70 Decreased By ▼ -0.81 (-7.71%)
FCCL 49.25 Decreased By ▼ -3.55 (-6.72%)
FCSC 4.50 Decreased By ▼ -0.71 (-13.63%)
FFL 16.95 Decreased By ▼ -1.33 (-7.28%)
FNEL 1.33 Increased By ▲ 0.07 (5.56%)
HUMNL 11.81 Decreased By ▼ -0.42 (-3.43%)
KEL 7.65 Decreased By ▼ -0.38 (-4.73%)
KOSM 3.90 Decreased By ▼ -0.51 (-11.56%)
MLCF 101.51 Decreased By ▼ -6.92 (-6.38%)
NBP 244.95 Decreased By ▼ -18.84 (-7.14%)
PACE 10.45 Decreased By ▼ -1.09 (-9.45%)
PAEL 47.80 Decreased By ▼ -1.08 (-2.21%)
PIAHCLA 23.12 Decreased By ▼ -1.69 (-6.81%)
PIBTL 17.39 Decreased By ▼ -1.29 (-6.91%)
PPL 221.30 Decreased By ▼ -7.72 (-3.37%)
PRL 27.90 Decreased By ▼ -3.07 (-9.91%)
PTC 56.02 Decreased By ▼ -3.20 (-5.4%)
SEARL 100.49 Decreased By ▼ -4.50 (-4.29%)
SSGC 28.00 Decreased By ▼ -2.62 (-8.56%)
TELE 8.60 Decreased By ▼ -0.85 (-8.99%)
THCCL 56.44 Decreased By ▼ -2.57 (-4.36%)
TPLP 8.87 Decreased By ▼ -0.68 (-7.12%)
TREET 23.78 Decreased By ▼ -2.19 (-8.43%)
TRG 52.16 Decreased By ▼ -5.80 (-10.01%)
WAVES 11.50 Decreased By ▼ -0.29 (-2.46%)
WTL 1.31 Decreased By ▼ -0.07 (-5.07%)

John Havlicek, a Hall of Famer and the Boston Celtics' all-time leading scorer, died Thursday in Florida. He was 79. Havlicek spent all 16 seasons of his NBA career with the Celtics, won eight NBA titles and was selected to the all-star team 13 times. He had been suffering from Parkinson's disease. The Celtics released a statement Thursday, describing Havlicek as "thoughtful and generous" and calling him the perfect team player.
"His defining traits as a player were his relentless hustle and wholehearted commitment to team over self," a team statement read. "John's passion and energy endeared him to basketball fans and made him a model for generations of NBA players."

Copyright Agence France-Presse, 2019

Comments

Comments are closed.